Becton, Dickinson and Company

BD sells products worldwide and organizes operations outside the United States across Europe, META, Greater Asia, Latin America, and Canada. The company disclosed that 2025 revenue was $12.79 billion in the United States and $9.05 billion internationally, meaning the U.S. remains the largest single market but international sales are nearly as important. International exposure is broad, with Greater Asia including China, Japan, South Asia, Southeast Asia, Korea, Australia, and New Zealand, while Latin America includes Mexico, Central America, the Caribbean, and South America. BD also highlighted emerging markets such as Eastern Europe, the Middle East and Africa, Latin America, and parts of Greater Asia as growth priorities. Geography matters because local procurement rules, reimbursement systems, currency swings, and government healthcare policies can materially affect demand and pricing, especially in China and other emerging markets.

BD faces a mix of company-specific execution risks and broad medtech industry risks. The company highlighted pressure from China volume-based procurement, compliance enforcement, and weaker government research funding, all of which can reduce volumes or delay customer purchases. As a global medical device manufacturer, BD is also exposed to inflation, supply chain disruption, tariffs, currency volatility, and higher interest rates, which can affect both demand and cost structure. Product quality, recalls, regulatory actions, and cybersecurity incidents are especially important because BD’s products are used in patient care and any defect can trigger liability, remediation costs, and reputational damage. Competition is intense across diagnostics, safety-engineered devices, and life sciences, with pricing pressure from low-cost manufacturers and specialized rivals.